Nothing Special   »   [go: up one dir, main page]

FR2881652B1 - Forme pharmaceutique orale microparticulaire anti-mesuage - Google Patents

Forme pharmaceutique orale microparticulaire anti-mesuage

Info

Publication number
FR2881652B1
FR2881652B1 FR0550364A FR0550364A FR2881652B1 FR 2881652 B1 FR2881652 B1 FR 2881652B1 FR 0550364 A FR0550364 A FR 0550364A FR 0550364 A FR0550364 A FR 0550364A FR 2881652 B1 FR2881652 B1 FR 2881652B1
Authority
FR
France
Prior art keywords
microparticular
measuring
oral pharmaceutical
pharmaceutical form
form anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0550364A
Other languages
English (en)
Other versions
FR2881652A1 (fr
Inventor
Gerard Soula
Florence Guimberteau
Remi Meyrueix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flamel Technologies SA
Original Assignee
Flamel Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0550364A priority Critical patent/FR2881652B1/fr
Application filed by Flamel Technologies SA filed Critical Flamel Technologies SA
Priority to PCT/EP2006/050784 priority patent/WO2006089843A2/fr
Priority to CNA2006800099754A priority patent/CN101151022A/zh
Priority to CA002596965A priority patent/CA2596965A1/fr
Priority to US11/883,935 priority patent/US20090041838A1/en
Priority to JP2007553626A priority patent/JP2008529990A/ja
Priority to EP06708128A priority patent/EP1845958A2/fr
Publication of FR2881652A1 publication Critical patent/FR2881652A1/fr
Application granted granted Critical
Publication of FR2881652B1 publication Critical patent/FR2881652B1/fr
Priority to US12/560,044 priority patent/US20100266701A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0550364A 2005-02-08 2005-02-08 Forme pharmaceutique orale microparticulaire anti-mesuage Expired - Fee Related FR2881652B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0550364A FR2881652B1 (fr) 2005-02-08 2005-02-08 Forme pharmaceutique orale microparticulaire anti-mesuage
CNA2006800099754A CN101151022A (zh) 2005-02-08 2006-02-08 抗滥用微粒口服剂型
CA002596965A CA2596965A1 (fr) 2005-02-08 2006-02-08 Forme medicamenteuse orale microparticulaire anti-mesusage
US11/883,935 US20090041838A1 (en) 2005-02-08 2006-02-08 Anti-Misuse Microparticulate Oral Drug Form
PCT/EP2006/050784 WO2006089843A2 (fr) 2005-02-08 2006-02-08 Forme medicamenteuse orale microparticulaire anti-mesusage
JP2007553626A JP2008529990A (ja) 2005-02-08 2006-02-08 誤用防止用の微小粒子状経口薬物形態
EP06708128A EP1845958A2 (fr) 2005-02-08 2006-02-08 Forme medicamenteuse orale microparticulaire anti-mesusage
US12/560,044 US20100266701A1 (en) 2005-02-08 2009-09-15 Anti-misuse microparticulate oral drug form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0550364A FR2881652B1 (fr) 2005-02-08 2005-02-08 Forme pharmaceutique orale microparticulaire anti-mesuage

Publications (2)

Publication Number Publication Date
FR2881652A1 FR2881652A1 (fr) 2006-08-11
FR2881652B1 true FR2881652B1 (fr) 2007-05-25

Family

ID=35058447

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0550364A Expired - Fee Related FR2881652B1 (fr) 2005-02-08 2005-02-08 Forme pharmaceutique orale microparticulaire anti-mesuage

Country Status (7)

Country Link
US (2) US20090041838A1 (fr)
EP (1) EP1845958A2 (fr)
JP (1) JP2008529990A (fr)
CN (1) CN101151022A (fr)
CA (1) CA2596965A1 (fr)
FR (1) FR2881652B1 (fr)
WO (1) WO2006089843A2 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme de liberation a base de polymere
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
EP1610767B1 (fr) 2003-03-26 2011-01-19 Egalet A/S Systeme de liberation regulee de morphine
WO2006133733A1 (fr) * 2005-06-13 2006-12-21 Flamel Technologies Forme posologique orale comportant un systeme anti-abus
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2219612A4 (fr) 2007-12-17 2013-10-30 Paladin Labs Inc Formulation à libération contrôlée évitant les utilisations impropres
FR2936709B1 (fr) * 2008-10-02 2012-05-11 Ethypharm Sa Comprimes alcoolo-resistants.
CA2746888C (fr) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Composition a liberation controlee prevenant un mesusage
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NO2403482T3 (fr) 2009-03-04 2018-05-26
DK2427177T3 (en) 2009-05-08 2018-06-18 Emplicure Ab Composition for prolonged drug delivery comprising geopolymer binder
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
JP6141583B2 (ja) * 2010-02-24 2017-06-07 シマ ラブス インク． 濫用耐性製剤
EP2549987A4 (fr) 2010-03-24 2015-01-21 Jazz Pharmaceuticals Inc Formes galéniques à libération contrôlée pour des substances médicamenteuses hydrosolubles et hygroscopiques à dose élevée
US9877925B2 (en) 2010-05-14 2018-01-30 Ethypharm Alcohol-resistant oral pharmaceutical form
US20130059010A1 (en) * 2010-05-14 2013-03-07 Ethypharm Alcohol-resistant oral pharmaceutical form
FR2960775A1 (fr) 2010-06-07 2011-12-09 Ethypharm Sa Microgranules resistants au detournement
JP5843864B2 (ja) 2010-09-07 2016-01-13 オレクソ・アクチエボラゲット 経皮薬物投与デバイス
MX2014015880A (es) 2012-07-06 2015-08-05 Egalet Ltd Composiciones farmaceuticas disuasivas de abuso para liberacion controlada.
CN105050708A (zh) 2012-11-14 2015-11-11 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
CN103330702B (zh) * 2013-07-02 2016-03-02 江苏长泰药业有限公司 含有拟交感神经胺盐和诱导凝胶体系的医药组合物
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (fr) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus a liberation immediate
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
KR20180025835A (ko) 2015-06-30 2018-03-09 다이이찌 산쿄 가부시키가이샤 남용 억제 특성을 갖는 의약 조성물
AU2017241266B2 (en) * 2016-03-31 2022-02-10 SpecGx LLC Extended release, abuse deterrent dosage forms
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3473246A1 (fr) 2017-10-19 2019-04-24 Capsugel Belgium NV Formulations anti-abus à libération immédiate
US11400052B2 (en) 2018-11-19 2022-08-02 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
CN110727226A (zh) * 2019-10-25 2020-01-24 河南大学 防止信息超载与作息紊乱的强弱电强制启闭系统
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477135A1 (fr) * 1990-09-07 1992-03-25 Warner-Lambert Company Microcapsules enduites sphéroidales mâchables et méthodes de leur préparation
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
EP1041988A4 (fr) * 1997-12-22 2002-03-13 Euro Celtique Sa Procede prevenant l'abus des doses orales d'opioides
CA2400567C (fr) * 2000-02-08 2008-01-15 Euro-Celtique S.A. Formes orales inviolables d'agonistes de l'opioide
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
FR2837100B1 (fr) * 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
ATE419840T1 (de) * 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
AU2003247876B2 (en) * 2002-07-05 2006-10-05 Collegium Pharmaceutical, Inc Abuse-deterrent pharmaceutical compositions of opiods and other drugs
FR2842735B1 (fr) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2878161B1 (fr) * 2004-11-23 2008-10-31 Flamel Technologies Sa Forme medicamenteuse orale, solide et concue pour eviter le mesusage
FR2878158B1 (fr) * 2004-11-24 2009-01-16 Flamel Technologies Sa Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage

Also Published As

Publication number Publication date
WO2006089843A2 (fr) 2006-08-31
US20100266701A1 (en) 2010-10-21
US20090041838A1 (en) 2009-02-12
FR2881652A1 (fr) 2006-08-11
WO2006089843A3 (fr) 2007-03-22
CA2596965A1 (fr) 2006-08-31
EP1845958A2 (fr) 2007-10-24
JP2008529990A (ja) 2008-08-07
CN101151022A (zh) 2008-03-26

Similar Documents

Publication Publication Date Title
FR2881652B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesuage
FR2892937B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesusage
NO20075628L (no) Farmasøytiske formuleringer
BRPI0511900A (pt) composições farmacêuticas
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
RU2398586C3 (ru) Фармацевтическая композиция
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
BRPI0714539A2 (pt) "formas farmacêuticas"
DK1957073T3 (da) Lægemiddel
DK1962873T3 (da) Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
FR2901478B1 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
BRPI0613033A2 (pt) composição oral
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
ATE453384T1 (de) Neue dosierformulierung
DK1837019T3 (da) Orale dispergerbare farmaceutiske sammensætninger
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
DK1587478T3 (da) Farmaceutisk sammensætning
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
MA28603B1 (fr) Composition pharmaceutique antimycobacterienne
DK1784174T3 (da) Famaceutisk sammensætning omfattende gabapentin
NO20034952D0 (no) Farmasöytiske forbindelser
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
DK1753431T3 (da) Farmaceutisk sammensætning omfattende ZD6474
NO20042027L (no) Oral composition
NL1025908A1 (nl) Farmaceutische combinatie.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20141031